No increased cancer risk found in rheumatology patients with history of malignancy taking DMARDS and TNF inhibitors


New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.

The ‘New York Times’ is changing Wordle’s rules

Previous article

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical’s Greg Mielke

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations